Prognosis and Treatment Planning for Myelodysplastic Syndromes

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: September 25, 2014
Expiration Date: September 25, 2015

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Myelodysplastic syndrome (MDS) is a disease of older persons; as such, the goals of care in elderly patients are different than those for younger patients. Join Dr. Mikkael Sekeres and Dr. Rafael Bejar as they discuss the different staging prognostic systems currently available and how genetic analysis may affect prognostic systems and ultimately the impact on tailoring therapy.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in managing patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Compare and contrast the different staging prognostic systems used in MDS including strengths and limitations of each system
  • Relate how genetic analysis including next-generation sequencing may affect prognostic systems
  • Describe the role staging/prognosis plays in tailoring therapy for patients with MDS


Staging Prognostic Systems – Mikkael A. Sekeres, MD, MS

Genetic Analysis and Sequencing – Rafael Bejar, MD, PhD

The Role of Staging/Prognosis in Tailoring Therapy – Mikkael A. Sekeres, MD, MS

Instructions for Participation and Credit

This activity is eligible for credit through September 25, 2015. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Mikkael A. Sekeres, MD, MS
Professor of Medicine
Director, Leukemia Program
Vice Chair for Clinical Research
Cleveland Clinic
Cleveland, Ohio

Dr. Mikkael Sekeres received his medical degree and a master of science degree in clinical epidemiology with a focus pharmacoepidemiology from the University of Pennsylvania. He was an internal medicine resident at Massachusetts General Hospital, Harvard University, and a hematology-oncology fellow at Dana-Farber Cancer Institute, Harvard University. Dr. Sekeres is a professor of medicine at Cleveland Clinic Lerner College of Medicine/hematologic oncology and blood disorders, with a joint appointment in translational hematology and oncology research. In addition he is director of the leukemia program, and vice chair for clinical research at the Cleveland Clinic Taussig Cancer Institute.

Dr. Sekeres is board certified in medical oncology by the American Board of Internal Medicine and holds memberships in the American Society of Clinical Oncology, American Society of Hematology, Southwest Oncology Group – Leukemia Committee, and the Northern Ohio Medical Association. He is on the editorial board of Journal of Clinical Oncology, Current Hematologic Malignancy Reports, Oncology Times, Blood Cancer Journal, and Nature, and he has written hundreds of editorials, articles, and abstracts. Dr. Sekeres’ specialty interests include leukemia, myelodysplastic syndromes, bone marrow failure syndromes, chronic lymphocytic leukemia, and chronic myelogenous leukemia.

Rafael Bejar, MD, PhD
Assistant Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Moores Cancer Center
La Jolla, California

Dr. Rafael Bejar received his medical degree and his PhD in neuroscience from the University of San Diego, California. He completed an internship in internal medicine at the University of Chicago and an internal medicine residency at Brigham and Women’s Hospital, as well as a hematology/oncology fellowship at Dana Farber Cancer Institute and Massachusetts General Hospital. Dr. Bejar is an assistant hematology/oncology professor at UCSD Moores Cancer Center in La Jolla, California.

Dr. Bejar has board certification in internal medicine, hematology/oncology, and medical oncology. He is currently investigating how mutations in the diseased cells of myelodysplastic syndrome patients are associated with response to drugs, and hopes to discover how these genes can be tested to select the best treatment options and give insight into the mechanisms of drug resistance and how to overcome them.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-024-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 14-024-352


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Mikkael Sekeres has received honoraria related to formal advisory activities from Boehringer Ingelheim GmbH, as well as consultant fees from Amgen Inc. and Celgene Corporation.

Dr. Rafael Bejar has received honoraria related to formal advisory activities from Celgene Corporation and Genoptix–a Novartis Company, as well as consultant fees from Genoptix.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Sekeres and Dr. Bejar have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Sekeres and Dr. Bejar have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.